Have any COVID-19 vaccines been associated with Guillain-Barré syndrome (GBS)?

Vaccine safety monitoring in the United States indicated an increased risk of GBS within 42 days of vaccination with the Janssen COVID-19 Vaccine, with the highest risk among people ages 40 through 64. Most reports were in males. Janssen COVID-19 Vaccine is no longer available in the United States.

Any FDA-authorized or FDA-licensed COVID-19 vaccine may be given to individuals with a history of GBS.